PHS
XLRN

PFM Health Sciences’s Acceleron Pharma XLRN Stock Holding History

PFM Health Sciences’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-61,400
Closed -$5.52M – 92
2020
Q1 		$5.52M Buy
+61,400
New +$4.77M 0.45% 52

Other funds holding XLRN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PFM Health Sciences's XLRN Position: Q2 2020 in Review

PFM Health Sciences sold out of Acceleron Pharma (XLRN) in Q2 2020, closing a stake of 61,400 shares — an estimated $5.52M sold.

PFM Health Sciences first reported a position in XLRN in Q1 2020 and held it in 1 quarter. The position peaked at $5.52M in Q1 2020. 242 funds tracked by Wall St. Rank hold XLRN as of Q2 2020.

  • PFM Health Sciences reported no remaining Acceleron Pharma position as of Q2 2020 after selling out during the quarter.
  • PFM Health Sciences sold 61,400 Acceleron Pharma shares in Q2 2020, an estimated $5.52M.
  • PFM Health Sciences first reported a position in Acceleron Pharma in Q1 2020 and held it in 1 quarter.
  • PFM Health Sciences's Acceleron Pharma position peaked at $5.52M in Q1 2020.
  • 242 funds tracked by Wall St. Rank held Acceleron Pharma as of Q2 2020.

Based on PFM Health Sciences's 13F filing for Q2 2020, filed 14 Aug 2020.